FTC to reverse past statements supporting PBMs; damage to Pfizer plant could compound shortages

Taking stock of the drug industry, from the lab to the medicine chest

July 20, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alex Brandon/AP STAT+ | FTC plans to reverse years of policy statements supporting pharmacy benefit managers "This new FTC statement will make a real difference in the ongoing legislative debate" about PBMs said former FTC policy director David Balto By Ed Silverman STAT+ | Damages from tornado at Pfizer plant could compound challenges of drug shortages The damages from a tornado that hit a Pfizer plant in North Carolina could compound the challenges of drug shortages. By Ed Silverman STAT+ | Vir antibody drug aimed at influenza A fails in clinical trial Vir's results are a setback in efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. By Jason Mast Sammy Kimball for STAT BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford Neil Kumar, CEO of BridgeBio, joins us this episode to talk about how his small company came to develop what could be a big drug. By Damian Garde and Meg Tirrell and Adam Feuerstein Key lawmaker blasts Congress' efforts on addiction: 'Shame on us' Paul Tonko says a largely incremental bill is "not meeting the moment" during a substance use and overdose epidemic. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser